Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?

Comments
Loading...
Zinger Key Points

These eleven large-cap stocks were the worst performers in the last week. Are they in your portfolio?

  1. FTAI Aviation Ltd. FTAI shares plummeted 35.42% after short seller firm Muddy Waters Research announced they initiated a short position in the company.
  2. Moderna, Inc. MRNA stock plunged 19.38% after the company updated its 2025 expected revenue range to $1.5 billion to $2.5 billion, below analyst estimates of $2.951 billion. Morgan Stanley maintained an Equal-Weight rating and lowered the price forecast from $70 to $38.
  3. GameStop Corporation GME stock declined 14.86%. In a recent X post, CNBC's Jim Cramer steered investors toward quantum stocks, suggesting they reinvest gains from GameStop into Rigetti Computing Inc RGTI.
  4. Snap Inc. SNAP shares dipped 12.91% following a report suggesting that Trump is considering an executive order to save TikTok from a U.S. ban.
  5. Rocket Lab USA, Inc. RKLB shares were down 10.81%. The company disclosed that its second Pioneer spacecraft for Varda Space Industries, Inc. is successfully operating in orbit.
  6. Natera, Inc. NTRA stock lost 9.51% last week despite Guggenheim raising the price forecast from $170 to $200. The company is due to provide a roadmap and outlook at the J.P. Morgan Healthcare Conference.
  7. Eli Lilly and Company LLY stock decreased 9.27%  after the company issued FY24 revenue guidance below the previous estimate.
  8. ICON plc ICLR stock fell 9.22% after the company issued FY25 guidance with its midpoint below estimates.
  9. BioNTech SE BNTX shares declined 8.89% after Moderna issued 2025 revenue guidance below analyst estimates.
  10. Novo Nordisk A/S NVO shares fell 8.89% after Ozempic and Wegovy were included in a list of 15 medications for Medicare drug price negotiations.
  11. BioMarin Pharmaceutical Inc. BMRN shares tumbled 8.68%. The company initiated a legal action against Ascendis Pharma A/S for infringement of European patent EP 3 175 863 B1 at the Unified Patent Court (UPC) in Munich, Germany.

Photos courtesy: Shutterstock

Got Questions? Ask
What impact will short positions have on FTAI?
Which biotech stocks are at risk after Moderna's guidance?
How might quantum technology stocks react to GameStop's decline?
Will Snap's stock continue to be affected by TikTok news?
How could Rocket Lab's performance influence space sector investments?
What opportunities exist in healthcare stocks following Natera's roadmap?
How will Eli Lilly's guidance affect the pharmaceutical sector?
Which companies could benefit from ICON's conservative FY25 guidance?
What implications does Medicare negotiations have for Novo Nordisk?
How will legal actions against Ascendis Pharma impact BioMarin's stock?
Market News and Data brought to you by Benzinga APIs

Posted In: